Financial Operations Insights, Guides, and Tools
Lab and Clinical Trial Spend: How to Set Up Spend Controls Without Slowing R&D
In the biotech world, spending and progress are intimately correlated. Every action taken, from experiments to patient enrolments to prototypes, moves a project forward incrementally, but it also burns up a lot of cash.
R&D Credit vs. Section 174: How They Work Together in Life Sciences
Life sciences companies, especially pre-revenue startups, are inordinately impacted by taxation. On the one hand, the R&D credit provides significant tax relief, covering up to 25% of qualified expenses; on the other hand, Section 174 requires some costs to be amortized over a period of years.
R&D Credit Documentation Is Getting Stricter: What Form 6765 Changes Mean for 2026
The R&D credit is a critical benefit for life sciences companies and other research-focused organizations. With the ability to cover up to 25% of qualified costs, the credit can significantly ease the tax burden, fuel innovation, and improve cash flow, even for pre-revenue companies.
Section 174 Domestic R&E Expensing in 2025: What’s Changed and How You Can Benefit
Section 174 reform under the One Big Beautiful Bill Act (OBBB) was a major turning point for companies heavily invested in R&E. As of the 2025 tax year, R&E expenses can be claimed immediately rather than being capitalized and amortized over several years.
R&D Tax Credit for Biotech and Life Sciences Companies: Eligibility, Documentation, and Examples
Biotech and life sciences firms invest significant resources in research and development. Fortunately, the government recognizes the value of this effort and offers tax credits to offset these costs, which can be a massive support for pre-revenue or unprofitable startups.
Section 174 for Life Sciences: How to Treat R&E Costs and Plan for Cash Taxes
We must understand that Section 174 is a cash tax issue, not just a compliance change. Clinical costs are often more exposed than you might think, and foreign research activity can dramatically increase taxable income and inflate liabilities.